BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38518601)

  • 1. Unlocking the effective alliance of β-lapachone and hydroxytyrosol against triple-negative breast cancer cells.
    Calahorra J; Blaya-Cánovas JL; Castellini-Pérez O; Aparicio-Puerta E; Cives-Losada C; Marin JJG; Rementeria M; Cara FE; López-Tejada A; Griñán-Lisón C; Aulicino F; Berger I; Marchal JA; Delgado-Almenta V; Granados-Principal S
    Biomed Pharmacother; 2024 May; 174():116439. PubMed ID: 38518601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1.
    Lin LC; Lee HT; Chien PJ; Huang YH; Chang MY; Lee YC; Chang WW
    Int J Med Sci; 2020; 17(14):2214-2224. PubMed ID: 32922184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
    Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
    Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways.
    Cruz-Lozano M; González-González A; Marchal JA; Muñoz-Muela E; Molina MP; Cara FE; Brown AM; García-Rivas G; Hernández-Brenes C; Lorente JA; Sanchez-Rovira P; Chang JC; Granados-Principal S
    Eur J Nutr; 2019 Dec; 58(8):3207-3219. PubMed ID: 30460610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Li JZ; Ke Y; Misra HP; Trush MA; Li YR; Zhu H; Jia Z
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):285-93. PubMed ID: 25448047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
    Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
    Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
    Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
    Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
    Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
    PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NQO1 is Required for β-Lapachone-Mediated Downregulation of Breast-Cancer Stem-Cell Activity.
    Kim DW; Cho JY
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30513573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of anethole and doxorubicin alleviates cell proliferation, cell cycle arrest, and ER stress and promotes ROS-mediated apoptosis in triple-negative breast cancer cells.
    Arumugam P; Sampathkumar B; Perumalsamy H; Balusamy SR; Ramesh V; Sundaravadevel S
    J Biochem Mol Toxicol; 2021 Dec; 35(12):e22928. PubMed ID: 34585488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
    Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
    Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxytyrosol and Oleuropein Inhibit Migration and Invasion of MDA-MB-231 Triple-Negative Breast Cancer Cell via Induction of Autophagy.
    Lu HY; Zhu JS; Zhang Z; Shen WJ; Jiang S; Long YF; Wu B; Ding T; Huan F; Wang SL
    Anticancer Agents Med Chem; 2019; 19(16):1983-1990. PubMed ID: 31333142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
    Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.